The selective serotonin reuptake inhibitor (SSRI) fluvoxamine offered pain relief in patients with prostatodynia, according to the results of a randomized controlled trial reported in the September issue of the Journal of Clinical Psychiatry.
“Prostatodynia is a common and often disabling condition that affects males and has the characteristics of a somatoform pain disorder,” write Douglas Turkington, FRCPsych, from the Royal Victoria Infirmary in Newcastle upon Tyne, and colleagues.
In this double-blind trial, 42 men with prostatodynia were randomized to treatment with fluvoxamine or placebo for up to eight weeks. Fluvoxamine dose was adjusted as needed, with median dose 150 mg (range 50-300 mg).
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!